Oxford BioTherapeutics Appoints Fandi Chief Medical Officer

Cancer drug developer Oxford BioTherapeutics (OBT) has appointed Abderrahim Fandi to serve in the newly created position of chief medical officer. Fandi comes to OBT from Celgene (NASDAQ: [[ticker:CELG]]). His experience also includes positions at Novartis (NYSE: [[ticker:NVS]]), Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), and AstraZeneca (NYSE: [[ticker:AZN]]). U.K.-based Oxford Bio, which maintains U.S. operations in San Jose, CA, has two Phase 1 programs. MEN1112 is being tested in acute myeloid leukemia; MEN1309 is in testing for breast, bladder and pancreatic cancers, as well as non-Hodgkin lymphoma.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan